When managing ulcerative colitis in older patients, understanding their overall health profile is key
- 5 Downloads
Ulcerative colitis (UC) in patients aged > 60 years is increasingly common. The treatment of UC aims to induce and maintain clinical remission, with 5-aminosalicylates the mainstay for mild UC. In moderate-to-severe or refractory UC, oral corticosteroids, thiopurines, anti-TNF agents, vedolizumab and tofacitinib are treatment options to induce and/or maintain remission. To facilitate compliance and minimize adverse drug events, treatment should be tailored to patients’ general health status, comorbidities and existing medications.
Compliance with ethical standards
The preparation of this review was not supported by any external funding.
Conflict of interest
The article was adapted from Drugs & Aging 2019; 36(1):13–27  by employees of Adis International Ltd/Springer Nature, who are responsible for the article content and declare no conflicts of interest.
- 4.Sturm A, Maaser C, Mendall M, et al. European Crohn’s and Colitis Organisation topical review on IBD in the elderly. J Crohns Colitis. 2017;11(3):263–73.Google Scholar
- 19.Parian A, Ha CY. Older age and steroid use are associated with increasing polypharmacy and potential medication interactions among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(6):1392–400.Google Scholar